Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global Compound Glycyrrhizin for Injection market was valued at USD 120 million in 2024 and is projected to reach USD 180 million by 2032, exhibiting a CAGR of 5.2% during the forecast period. The U.S. market accounted for approximately 25% of global revenue in 2024, while China's market is growing rapidly with an estimated 8% year-on-year increase.
Compound Glycyrrhizin for Injection is a pharmaceutical formulation containing glycyrrhizin, a bioactive compound extracted from licorice root. This medication demonstrates significant anti-inflammatory and hepatoprotective effects, making it clinically valuable for treating chronic liver diseases including hepatitis B/C and cirrhosis. The intravenous formulation ensures rapid bioavailability for acute therapeutic interventions.
The market growth is driven by increasing liver disease prevalence worldwide, with WHO estimating 325 million hepatitis B/C cases globally. Pharmaceutical companies are expanding production capabilities to meet demand - 9 major Chinese manufacturers collectively control over 60% market share. Recent regulatory approvals in emerging markets and clinical studies exploring expanded applications for dermatological conditions are creating new growth opportunities in this specialized therapeutic segment.
Growing Demand for Liver Disease Treatments
The Compound Glycyrrhizin for Injection market is experiencing significant growth due to the rising prevalence of liver diseases globally. With over 1.5 billion people affected by chronic liver conditions, the need for effective hepatoprotective drugs like Compound Glycyrrhizin is increasing. Its anti-inflammatory and immunomodulatory properties make it a preferred treatment option.
Expanding Applications in Chronic Hepatitis
Medical research has validated Compound Glycyrrhizin's efficacy in treating chronic hepatitis B and C, driving its adoption in clinical settings. Hospitals and clinics are increasingly incorporating this treatment into their protocols as part of comprehensive liver care programs.
The global market for liver disease therapeutics is projected to grow at 6.8% CAGR, with Compound Glycyrrhizin capturing a significant share of this expansion
Pharmaceutical companies are investing in enhanced formulations of Compound Glycyrrhizin injections to improve bioavailability and patient outcomes.
MARKET CHALLENGES
Regulatory Hurdles and Approval Processes
Despite its therapeutic benefits, Compound Glycyrrhizin for Injection faces stringent regulatory requirements in many countries. The complex approval process for injectable formulations can delay market entry and increase development costs.
Other Challenges
Limited Awareness in Emerging Markets
Medical practitioners in developing regions often lack familiarity with Compound Glycyrrhizin's therapeutic applications, creating adoption barriers.
Competition from Alternative Therapies
Established hepatoprotective drugs and emerging biologics present strong competition, requiring differentiation strategies.
Safety Concerns and Side Effects
Potential side effects such as pseudoaldosteronism and hypertension associated with long-term use of Compound Glycyrrhizin injections may restrain market growth. Healthcare providers often exercise caution when prescribing this treatment, especially for patients with pre-existing conditions.
Expansion in Emerging Economies
Asia-Pacific markets with high hepatitis prevalence present significant growth opportunities. Countries like China and India, where liver disease burden is substantial, offer untapped potential for Compound Glycyrrhizin for Injection adoption.
Combination Therapies Development
Research into combination treatments pairing Compound Glycyrrhizin with other hepatoprotective agents could open new market segments. Such therapeutic combinations may improve treatment efficacy and patient outcomes.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Intravenous Injection dominates due to its rapid onset of action and preferred administration method in acute liver conditions. The segment benefits from standardized dosage forms and widespread clinical adoption for emergency hepatic treatments. |
| By Application |
|
Chronic Liver Disease remains the primary application due to glycyrrhizin's proven hepatoprotective effects. The segment sees growing adoption for managing hepatitis complications, while dermatological applications are gaining traction in Asia-Pacific markets. |
| By End User |
|
Hospitals maintain leadership due to high patient volumes requiring injectable liver therapies. Specialty clinics show growing demand for outpatient administration, while research institutes drive innovation in expanded therapeutic applications. |
| By Therapeutic Protocol |
|
Combination Therapy emerges as preferred protocol, particularly when paired with antiviral treatments for hepatitis. The segment benefits from synergistic effects that improve patient outcomes while mitigating potential side effects of glycyrrhizin monotherapy. |
| By Formulation Type |
|
Standard Formulation maintains dominance through established manufacturing processes and regulatory approvals. However, preservative-free variants are gaining preference in pediatric and sensitive patient populations, driving formulation innovation. |
China Dominates Global Production with Established Pharmaceutical Leaders
The Compound Glycyrrhizin for Injection market is highly concentrated in China, with Shanxi PUDE Pharmaceutical and Xi'an Lijun Pharmaceutical leading the industry. These top five manufacturers collectively hold significant market share, benefiting from established production facilities and regulatory approvals in key therapeutic applications including chronic liver diseases. Their dominance is further strengthened by vertical integration and strategic partnerships across the pharmaceutical supply chain.
Niche players like Beijing Kawin Technology Share-Holding and CSPC OUYI Pharmaceutical are expanding their footprint through specialized formulations and regional distribution networks. Emerging manufacturers are focusing on intravenous drip formulations to address the growing demand in dermatology applications, competing through pricing strategies and hospital procurement channels.
List of Key Compound Glycyrrhizin for Injection Companies ProfiledShanxi PUDE Pharmaceutical
Xi'an Lijun Pharmaceutical
Beijing Kawin Technology Share-Holding
Cisen Pharmaceutical
Harbin Medisan Pharmaceutical
Anhui Hongye Pharmaceutical
Chengdu Easton Bio Pharmaceuticals
Xiuzheng Pharmaceutical Group
Nanjing Jinglian Pharmaceutical
Shandong Lukang Pharmaceutical
Guangdong Zhongsheng Pharmaceutical
The global Compound Glycyrrhizin for Injection market, valued at $XX million in 2024, is projected to reach $XX million by 2032 with a CAGR of X.X%. This growth is driven by rising prevalence of chronic liver diseases, particularly hepatitis B and C, where glycyrrhizin shows significant therapeutic efficacy. The Asia-Pacific region, led by China, dominates market demand due to high disease burden.
Other TrendsType Segment Dynamics
Intravenous injection remains the dominant administration method, accounting for XX% of the market in 2024. However, intravenous drip solutions are showing faster growth at X.X% CAGR due to improved patient outcomes in prolonged therapy regimens.
Competitive Landscape ShiftsChina maintains manufacturing leadership with Shanxi PUDE Pharmaceutical and CSPC OUYI Pharmaceutical collectively representing XX% of global revenue. Market consolidation continues with North China Pharmaceutical acquiring two regional producers in 2024 to strengthen its supply chain for European expansion.
Therapeutic Application Expansion
While chronic liver diseases constitute XX% of current usage, dermatology applications (eczema, dermatitis) are emerging as high-growth segments, projected to grow at X.X% annually through 2032. Clinical trials for new indications including autoimmune disorders show promising early results.
Regional Market DevelopmentsThe U.S. market reached $XX million in 2024 with FDA approvals accelerating. Europe shows adoption rates increasing as EMA guidelines clarify glycyrrhizin's role in integrated liver treatment protocols. Emerging markets in Southeast Asia and Latin America demonstrate the fastest growth at XX% CAGR.
Regional Analysis: Compound Glycyrrhizin for Injection MarketEurope
European demand concentrates in Germany, France and Italy where compounding pharmacies prepare glycyrrhizin injections under physician prescriptions. The market operates through specialized channels with strict regulatory oversight requiring comprehensive documentation of traditional use. Homeopathic practitioners drive significant off-label use, particularly for dermatological and anti-inflammatory applications. Some hospitals cautiously integrate glycyrrhizin as adjunctive therapy in regulatory-approved contexts. Manufacturers face increasing pressure to provide extensive pharmacological data for sustained market access.
North America
The U.S. market remains constrained by regulatory barriers but shows growing interest in glycyrrhizin research applications. Specialty clinics focusing on integrative medicine account for most usage, sourcing products through compounding pharmacies. Clinical trials investigating glycyrrhizin's potential in COVID-19 treatment generated temporary demand spikes. Natural product manufacturers lobby for expanded injectable classification options. Canada maintains slightly more flexible regulations, particularly in British Columbia where traditional Chinese medicine practitioners have established injection protocols.
Middle East & Africa
Gulf Cooperation Council countries exhibit moderate growth as hospitals incorporate glycyrrhizin in complementary cancer care protocols. South Africa represents the most developed market with established supply chains for Chinese-manufactured injections. Regulatory frameworks remain underdeveloped across most African nations, limiting commercial expansion despite growing traditional medicine utilization for chronic diseases.
South America
Fragmented regulations create uneven access to glycyrrhizin injections across South American markets. Brazil and Argentina show strongest demand through integrative oncology centers and specialized therapy clinics. Local production remains limited, necessitating imports primarily from Chinese manufacturers. Governments increasingly recognize traditional medicine in healthcare policies, potentially opening new pathways for injectable formulations.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Healthcare providers and hospital systems
Medical device manufacturers
Contract research organizations
Investors and policy makers
-> Global Compound Glycyrrhizin for Injection market was valued at USD 120 million in 2024 and is projected to reach USD 180 million by 2032.
-> Key players include Shanxi PUDE Pharmaceutical, Xi'an Lijun Pharmaceutical, Beijing Kawin Technology Share-Holding, and CSPC OUYI Pharmaceutical, among others.
-> Key growth drivers include rising prevalence of liver diseases, increasing hepatitis B/C cases, and expanding clinical applications.
-> Asia-Pacific is the dominant market, with China accounting for significant production and consumption.
-> Emerging trends include expanded therapeutic applications in dermatology and new regulatory approvals in emerging markets.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates